Morphine-6β-glucuronide induces potent immunomodulation

International Immunopharmacology

Volumn 1, Issue 5, 2001, Pages 821-831

  Carrigan, Kelly A ^a   Lysle, Donald T ^a  

^a University of North Carolina at Chapel Hill   (United States)

Author keywords

Antinociception; Concanavalin A; Lewis rat; Lipopolysaccharide; Metabolite; Morphine 6 glucuronide; Neuroimmunomodulation; Opioid

Indexed keywords

CONCANAVALIN A; GAMMA INTERFERON; LIPOPOLYSACCHARIDE; MORPHINE 6 GLUCURONIDE; MORPHINE DERIVATIVE; OPIATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CELL ACTIVITY; CONTROLLED STUDY; IMMUNE STATUS; IMMUNOMODULATION; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; MALE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RAT;

ADJUVANTS, IMMUNOLOGIC; ANALGESICS; ANIMALS; B-LYMPHOCYTES; INJECTIONS, INTRAVENTRICULAR; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE II; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MALE; MORPHINE; MORPHINE DERIVATIVES; RATS; RATS, INBRED LEW; T-LYMPHOCYTES;

EID: 0035072635     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(01)00020-0     Document Type: Article

References (46)

1. Morphine inhibition of lymphocyte activity is mediated by an opioid-dependent mechanism
2. Morphine-induced alterations of immune status: Dose-dependency and compartment specificity and antagonism by naltrexone
3. Involvement of brain opiate receptors in the immune-suppressive effect of morphine
4. Effects of a single administration of morphine or footshock stress on natural killer cell cytotoxicity
5. Distinction between the in vitro and in vivo inhibitory effects of morphine on lymphocyte proliferation based on agonist sensitivity and naltrexone reversibility
6. Immunosuppressive effects of chronic morphine treatment in mice
7. Morphine pellet-induced immunomodulation in mice: Temporal relationships
8. Evidence for β-adrenergic receptor involvement in the immunomodulatory effects of morphine
9. Suggestive evidence for receptors for morphine and methionine enkephalin on normal human blood T-lymphocytes
10. The kappa-opioid receptor expressed on the mouse lymphoma cell line R1.1 contains a sulfhydryl group at the binding site
11. Kappa-opioid receptors expressed on three related thymoma cell lines: Differences in receptor-effector coupling
12. Binding of naloxone to human T lymphocytes
13. Opiate receptors on lymphocytes and platelets in man
14. Characterization of opiate binding sites on membranes of rat lymphocytes
15. Effects of high doses of morphine on Con-A induced lymphokine production in vitro
16. Inhibition by opioids of phagocytosis in peritoneal macrophages
17. Immunomodulatory activity of mu- and kappa-selective opioid agonists
18. Assessment of the involvement of central nervous system and peripheral opioid receptors in the immunomodulatory effects of acute morphine treatment in rats
19. Evidence for the involvement of the caudal region of the periaqueductal grey in a subset of morphine-induced alterations of immune status
20. The periaqueductal grey matter mediates opiate-induced immunosuppression
21. Glucuronidation of morphine in human fetal and adult liver
22. Further evidence that morphine-6-β-glucuronide is a more potent opioid agonist than morphine
23. Oral morphine in cancer patients: In vivo kinetics and in vitro hepatic glucuronidation
24. Morphine-6beta-glucuronide, a potent mu agonist
25. Antinociceptive and ventilatory effects of the morphine metabolites: Morphine-6-glucuronide and morphine-3-glucuronide
26. Analgesic effects of morphine glucuronides
27. Morphine-6-glucuronide: Analgesic effects and receptor binding profile in rats
28. Pharmacological characterization of morphine-6-beta-glucuronide, a very potent morphine metabolite
29. Analgesic response and plasma and brain extracellular fluid pharmacokinetics or morphine and morphine-6-β-d-glucuronidation
30. The analgesic activity of morphine-6-glucuronide
31. Immunomodulatory effects of in vitro exposure to morphine and its metabolites
32. Comparison of the time course of morphine's analgesic and immunologic effects
33. The standardization of NK cell assay for studies of biological response modifiers
34. Phenotypic and functional assessments of immune status in the rat spleen following acute heroin treatment
35. Blood-brain barrier permeability to morphine-beta-glucuronide is markedly reduced compared to morphine
36. Different biotransformation of morphine in isolated liver cells from guinea pig and rat
37. The enantioselective glucuronidation of morphine in rats and humans: Evidence for the involvement of more than one UDP-glucuronosyltransferase isoenzyme
38. Comparison of the discriminative and antinociceptive effects of morphine and its glucuronide metabolites after central or systemic administration in the rat
39. Potency ratios of morphine and morphine-6β-glucuronide analgesia elicited form the periaqueductal gray, locus coeruleus or rostral ventromedial medulla of rats
40. Intrathecal morphine-3-glucuronide does not antagonize spinal antinociception by morphine or morphine-6-glucuronide in rats
41. Analgesic responses to intrathecal morphine in relation to CSF concentrations of morphine-3, β-glucuronide and morphine-6,β-glucuronide
42. Potential analgesic contribution from morphine-6-glucuronide in CSF
43. The metabolite morphine-6beta-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function
44. Morphine and its 3- and 6β-glucuronides in plasma and urine during chronic administration in cancer patients
45. Morphine and morphine-6-glucuronide plasma concentrations and effects in cancer pain